The aim is to evaluate the therapeutic potential of a frataxin peptide delivered via hematopoietic stem cells in Friedreich's ataxia models.
Hematopoietic stem and progenitor cells (HSPCs) were genetically modified to express frataxin peptide.
The modified cells were differentiated into macrophages to assess peptide secretion.
Long-term effects of the peptide on Friedreich's ataxia stabilization were analyzed.
HSPCs differentiated into functional macrophages that successfully secreted the frataxin peptide.
The therapy led to stabilization of Friedreich's ataxia in model systems, indicating potential for clinical application.
Abstract
HSPCs transduced with the vector differentiated normally into macrophages and secreted the peptide. These results support a cell and gene therapy strategy for long-term stabilization of FRDA.